Comorbidities and mortality risk among extensive-stage small-cell lung cancer patients in mainland China: impacts of hypertension, type 2 diabetes mellitus, and chronic hepatitis B virus infection
Autor: | Min Yu, Youling Gong, Yin Huang, Yanying Li, Weigang Xiu |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Male China Cancer Research medicine.medical_specialty Lung Neoplasms hypertension Multivariate analysis Kaplan-Meier Estimate Clinical Reports Virus Hepatitis B Chronic hepatitis B virus infection Chronic hepatitis Internal medicine medicine Humans Pharmacology (medical) Lung cancer extensive-stage small-cell lung cancer Aged Neoplasm Staging Pharmacology business.industry Hazard ratio Type 2 Diabetes Mellitus Middle Aged medicine.disease Small Cell Lung Carcinoma Progression-Free Survival Confidence interval Diabetes Mellitus Type 2 Oncology mortality risk Female type 2 diabetes business Extensive-stage small cell lung cancer |
Zdroj: | Anti-Cancer Drugs |
ISSN: | 0959-4973 |
Popis: | The present study investigated the impact of major comorbidities, including hypertension, type 2 diabetes mellitus (T2DM), and chronic hepatitis B virus (HBV) infection, on the progression-free survival (PFS) and overall survival (OS) of extensive-stage small-cell lung cancer (ES-SCLC) patients in China. Patients having a pathologic diagnosis of ES-SCLC between 2009 and 2017 were enrolled and grouped according to their specific comorbidities. The PFS and OS for each group were evaluated using the Kaplan–Meier method and Cox proportional hazard models. In total, 632 patients were analyzed. The median PFS (mPFS) of these patients was 9 months [95% confidence interval (CI), 6–12 months]. The mPFS of patients without hypertension or T2DM was 9 months; conversely, it was significantly reduced for patients with hypertension [7 months (P < 0.0001)] or T2DM [5 months (P < 0.0001)]. However, mPFS was not significantly different between patients with and without HBV infection (P = 0.2936). A similar trend was observed for OS as well. Further multivariate analyses showed that the OS of patients with hypertension [hazard ratio (HR), 1.344; 95% CI, 1.073–1.683; P = 0.010] or T2DM (HR, 1.455; 95% CI, 1.134–1.868; P = 0.003) was significantly shorter than that of patients without these comorbidities. Accordingly, mortality risk was the highest in patients with concurrent hypertension and T2DM (HR, 1.665; 95% CI, 1.037–2.672; P = 0.00058). Our study found that hypertension and T2DM may be associated with a worse prognosis in ES-SCLC patients. Considerable attention should be paid to the accompanying anti-comorbidity therapies available for patients with ES-SCLC. |
Databáze: | OpenAIRE |
Externí odkaz: |